Shane O'Grady

Shane O'Grady

Auto-generated profile, based on publicly available information

Shane O'Grady

Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
SOS. O'GRady
S. O'GRady
MMMaria Morgan
Maria Morgan

1 December 2014 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
SOShane O’grady
Shane O’grady
SFStephen Patrick Finn
Stephen Patrick Finn
SCSinead Cuffe
Sinead Cuffe
DRDerek Richard
Derek Richard
Kenneth O'ByrneKenneth O'Byrne
Kenneth O'Byrne
MBMartin Barr
Martin Barr

16 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MDMichael Joseph Duffy
Michael Joseph Duffy
MTMinhong Tang
Minhong Tang
SRSubhasree Rajaram
Subhasree Rajaram
SOShane O’grady
Shane O’grady
JCJohn Crown
John Crown
Mutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug, several new strategies have recently become available for targeting the mutant protein. One of the most promising of these involves the use of low molecular weight compounds that promote refolding and reactivation of mutant p53 to its wild-type form. Several such reactivating drugs are currently undergoing evaluation in clinical trials, including eprenetapopt (APR-246), COTI-2, arsenic trioxide and PC14586. Of these, the most clinically advanced for targeting mutant p53 is eprenetapopt which has completed phase I, II and III clinical trials, the latter in patients with mutant TP53 myelodysplastic syndrome. Although no data on clinical efficacy are currently available for eprenetapopt, preliminary results suggest that the drug is relatively well tolerated. Other strategies for targeting mutant p53 that have progressed to clinical trials involve the use of drugs promoting degradation of the mutant protein and exploiting the mutant protein for the development of anti-cancer vaccines. With all of these ongoing trials, we should soon know if targeting mutant p53 can be used for cancer treatment. If any of these trials show clinical efficacy, it may be a transformative development for the treatment of patients with cancer since mutant p53 is so prevalent in this disease.

24 January 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SOShane O’gRady
Shane O’gRady
MMMaria Morgan
Maria Morgan
Microcalcifications are vital mammographic indicators contributing to the early detection of up to 50% of non-palpable tumours and may also be valuable as prognostic markers. However, the precise mechanism by which they form remains incompletely understood. Following development of an in vitro model using human breast cancer cells lines cultured with a combination of mineralisation-promoting reagents, analysis of calcium deposition, alkaline phosphatase (ALP) activity and changes in expression of key genes was used to monitor the calcification process. Two cell lines were identified as successfully mineralising in vitro, MDA-MB-231 and SKBR3. Mineralising cell lines displayed higher levels of ALP activity that was further increased by addition of mineralisation promoting media. qPCR analysis revealed changes in expression of both pro- (RUNX2) and anti- (MGP, ENPP1) mineralisation genes. Mineralisation was suppressed by chelation of intracellular Ca2+ and inhibition of TRPM7, demonstrating a functional role for the channel in formation of microcalcifications. Increased Mg2+ was also found to effectively reduce calcium deposition. These results expand the number of human breast cancer cell lines with a demonstrated in vitro mineralisation capability, provide further evidence for the role of an active, cellular process of microcalcification formation and demonstrate for the first time a role for TRPM7 mediated Ca2+ transport.

6 September 2016 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
GKGraeme Kelly
Graeme Kelly
AKA. Foltyn-Arfa Kia
A. Foltyn-Arfa Kia
FHF. Hassan
F. Hassan
SOS. O'GRady
S. O'GRady
MMMaria Morgan
Maria Morgan
MDMarc Devocelle
Marc Devocelle
The first targeted anticancer polymeric prodrug candidates of antimicrobial peptides, intended for combination therapy with another polymeric prodrug of an approved antineoplastic agent (doxorubicin) are reported.

1 July 2021 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
SOShane O’gRady
Shane O’gRady
MMMaria Morgan
Maria Morgan